OncoMatch/Clinical Trials/NCT06036745
Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen
Is NCT06036745 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pembrolizumab + SOX for gastric cancer stage iiib-iiic.
Treatment: Pembrolizumab + SOX — it is an an Exploratory Single-Arm, Single-Center Study of Pembrolizumab in Combination with SOX Regimen for Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Biomarker criteria
Required: MSI high-frequency microsatellite instability
Consistent with high-frequency microsatellite instability MSI-H
Required: PD-L1 (CD274) high expression (CPS score ≥5)
High expression of PD-L1 (CPS score ≥5)
Disease stage
Required: Stage IIIB, IIIC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgery — adjuvant
after radical resection
Cannot have received: anti-tumor immunotherapy
Have not received anti-tumor immunotherapy
Lab requirements
Blood counts
hemoglobin ≥90g/l; absolute neutrophil count ≥1.5×109/ l; platelet count ≥100×109/ l
Liver function
aspartate or alanine aminotransferase ≤ 2.5 times the upper limit; alkaline phosphatase ≤ 2.5 times the upper normal limit
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify